News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

UK's National Institute for Clinical Excellence (NICE) Rejects AstraZeneca PLC (AZN) Faslodex Breast Cancer Drug



11/10/2011 7:00:05 AM

AstraZeneca's breast cancer drug Faslodex has been rejected for use on Britain's state health service, dealing a blow to a product that has been on the market in Europe since 2004. The National Institute for Health and Clinical Excellence (NICE) said on Thursday in its final appraisal that it had not found any evidence Faslodex worked significantly better than existing treatments, so its widespread use would not be a good use of resources. AstraZeneca had estimated Faslodex, an injection, could extend life when compared to using the company's own aromatase inhibitor tablets Arimidex or Novartis's Femara, but NICE found this to be "considerably uncertain".

Read at Reuters
Read at Fox News
Read at Bloomberg
Read at News Release
Read at InPharm.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES